Zymeron applies bioinspired polymer innovations to develop antibody-like affinity beads and particles as synthetic, non-biological materials for bioseparations and purification including protein purification and selective removal and recovery of molecules from wastewater and human wastes. It offers a highly performing, cost-effective alternative to the state-of-the-art purification techniques. Zymeron is actively pursuing product development opportunities in anti-fouling coating and superhydrophilic surfaces for medical device applications. 


Zymeron is developing a portfolio of polymer-based drug formulation and delivery technologies. 1) Long-lasting, biodegradable subdermal implants for therapeutic and prophylactic drugs. 2) Extended release tablet and capsule formulations targeting different regions of the gastrointestinal tract. 3) Topical gels and sprays for the delivery of medical countermeasures against skin persistent and dermal penetrable toxins. 4) Beyond-PEG, next generation polymer technologies for extended circulation of biological drugs and for the mitigation or prevention of host immune responses.

  


 Diagnostic Assays

Bioinspired Innovation 

Bioseparations

At Zymeron, we innovate in bioinspired polymer materials and materials systems to achieve critical biological functions. By precisely engineering the material formulation and fabrication process our materials are made smarter enabling on-demand and intelligent response to biological and environmental conditions. Interactions between our materials and the biological systems are controlled at the molecular level achieving results that have not been realized previously. Zymeron is developing a portfolio of bio/polymer interfacing technologies and materials, and is transitioning laboratory ideas and innovations to practical solutions and higher-performing products.     

Drug Formulation

Zymeron develops novel particle and surface coating technologies using its proprietary polymer materials innovations. One primary application is the minimization of non-specific binding in the development of in vitro diagnostic tests. Extremely low background signals and non-specific binding significantly improved the assay sensitivity, limit of detection and limit of quantification. Our technologies enable device miniaturization and laboratory tests-matching diagnostic accuracy to be achieved at the same time for point of care (POC) tests.